Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF, and MACCE. Echocardiographic LVH was present in 33% of 379 hypertensive patients. AF progression after 1 year occurred in 10.2% of 373 patients with rhythm follow-up. In hypertensive patients with LVH, AF progression occurred more frequently as compared with hypertensive patients without LVH (23.3% vs 8.8%, p = 0.011). In hypertensive AF patients, LVH was the most important multivariably adjusted determinant of AF progression on multivariable logistic regression (odds ratio 4.84, 95% confidence interval 1.70 to 13.78, p = 0.003). This effect was only seen in male patients (27.5% vs 5.8%, p = 0.002), while in female hypertensive patients, no differences were found in AF progression rates regarding the presence or absence of LVH (15.2% vs 15.0%, p = 0.999). No differences were seen in MACCE for hypertensive patients with and without LVH. In conclusion, in men with hypertension, LVH is associated with AF progression. This association seems to be absent in hypertensive women.
Erkuner O., Dudink E.A.M.P., Nieuwlaat R., Rienstra M., Van Gelder I.C., Camm A.J., et al. (2018). Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). THE AMERICAN JOURNAL OF CARDIOLOGY, 122(4), 578-583 [10.1016/j.amjcard.2018.04.053].
Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)
Erkuner O.;Dudink E. A. M. P.;Nieuwlaat R.;Rienstra M.;Van Gelder I. C.;Camm A. J.;Capucci A.;Breithardt G.;LeHeuzey J. -Y.;Lip G. Y. H.;Crijns H. J. G. M.;Luermans J. G. L. M.;Andresen D.;Davies W.;Levy S.;Olsson B.;Aliot E.;Cobbe S.;Santini M.;Vardas P.;Manini M.;Bramley C.;Laforest V.;Taylor C.;Del Gaiso S.;Huber K.;De Backer G.;Sirakova V.;Cerbak R.;Thayssen P.;Lehto S.;Blanc J. -J.;Delahaye F.;Kobulia B.;Zeymer U.;Cokkinos D.;Karlocai K.;Graham I.;Shelley E.;Behar S.;Maggioni A.;Goncalves L.;Grabauskiene V.;Asmussen I.;Deckers J.;Stepinska J.;Mareev V.;Vasiljevic Z.;Riecansky I.;Kenda M. F.;Alonso A.;Lopez-Sendon J. L.;Rosengren A.;Buser P.;Okay T.;Sychov O.;Fox K.;Schofield P.;Simoons M.;Wood D.;Battler A.;Boersma E.;Fox K.;Komajda M.;McGregor K.;Mulder B.;Priori S.;Ryden L.;Vahanian A.;Wijns W.;Sanofi-Aventis;Grigoryan S. V.;Apetyan I.;Aroyan S.;Azarapetyan L.;Anvari A.;Gottsauner-Wolf M.;Pfaffenberger S.;Aydinkoc K.;Kalla K.;Penka M.;Drexel H.;Langer P.;Pierard L. A.;Legrand V.;Blommaert D.;Schroeder E.;Mancini I.;Geelen P.;Brugada P.;De Zutter M.;Vrints C.;Vercammen M.;Morissens M.;Borisov B.;Petrov V. A.;Marinova M.;Assen A.;Goudev R.;Peychev Y.;Stoyanovsky V.;Stoynev E.;Kranjcevic S.;Moutiris J.;Ioannides M.;Evequoz D.;Spacilova J.;Novak M.;Eisenberger M.;Mullerova J.;Kautzner J.;Riedlbauchova L.;Petru` J.;Taborsky M.;Cappelen H.;Sharaf Y. A.;Ibrahim B. S. S.;Tammam K.;Saad A.;Elghawaby H.;Sherif H. Z.;Farouk H.;Mielke A.;Engelen M.;Kirchhof P.;Zimmermann P.;Aviles F. F.;Rubio J.;Malpartida F.;Corona M.;Sanchez L. T.;Miguel J.;Herrera L.;Quesada A.;Garcia A. J. M.;Gonzalez C. S.;Juango M. S. A.;Berjon-Reyero J.;Alegret J. M.;Fernandez J. M. C.;Carrascosa C.;Romero R. A. F.;Lara M. G.;Sendon J. L. L.;de Diego J. J. G.;Martin L. S.;Irurita M.;Guttierez N. H.;Rubio J. R. S.;Antorrena I.;Paves A. B.;Salvador A.;Orriach M. D.;Garcia A. A.;Epelde F.;Martinez V. B.;Sanchez A. B.;Galvez C. P.;Rivero R. F.;Madrid A. H.;Baron-Esquivias G.;Peinado R.;Guindal J. A. G.;Vera T. R.;Fernandez E. L.;Gayan R.;Garcia J.;Bodegas A.;Lopez J. T.;Florez J. M.;Cabezas C. L.;de Castroviejo E. V. R.;Bellido J. M.;Ruiz M. E.;Savolainen K.;Nieminen M.;Toivonen L.;Syvanne M.;Pietila M.;Galley D.;Beltra C.;Gay A.;Daubert J. C.;Lecocq G.;Poulain C.;Cleland J. G. F. C.;Shelton R.;Choudhury A.;Abuladze G.;Jashi I.;Tsiavou A.;Giamouzis G.;Dagres N.;Kostopoulou A.;Tsoutsanis D.;Stefanadis C.;Latsios G.;Vogiatzis I.;Gotsis A.;Bozia P.;Karakiriou M.;Koulouris S.;Parissis J.;Kostakis G.;Kouris N.;Kontogianni D.;Athanasios K.;Douras A.;Tsanakis T.;Marketou M.;Patsourakos N.;Czopf L.;Halmosi R.;Preda I.;Csoti E.;Badics A.;Strasberg B.;Freedberg N. A.;Katz A.;Zalzstein E.;Grosbard A.;Goldhammer E.;Nahir M.;Epstein M.;Vider I.;Luria D.;Mandelzweig L.;Aloisi B.;Cavallaro A.;Antonielli E.;Doronzo B.;Pancaldo D.;Mazzola C.;Buontempi L.;Calvi V.;Giuffrida G.;Figlia A.;Ippolito F.;Gelmini G. -P.;Gaibazzi N.;Ziacchi V.;De Tommasi F.;Lombardi F.;Fiorentini C.;Terranova P.;Maiolino P.;Albunni M.;Pinna-Pintor P.;Fumagalli S.;Masotti G.;Boncinelli L.;Rossi D.;Santoro G. M.;Fioranelli M.;Naccarella F.;Maranga S. S.;Lepera G.;Bresciani B.;Seragnoli E.;Forti M. C.;Cortina V.;Baciarello G.;Cicconetti P.;Lax A.;Vitali F.;Igidbashian D.;Scarpino L.;Terrazzino S.;Tavazzi L.;Cantu F.;Pentimalli F.;Novo S.;Coppola G.;Zingarini G.;Ambrozio G.;Moruzzi P.;Callegari S.;Saccomanno G.;Russo P.;Carbonieri E.;Paino A.;Zanetta M.;Barducci E.;Cemin R.;Rauhe W.;Pitscheider W.;Meloni M.;Marchi S. M.;Di Gennaro M.;Calcagno S.;Squaratti P.;Quartili F.;Bertocchi P.;De Martini M.;Mantovani G.;Komorovsky R.;Desideri A.;Celegon L.;Tarantini L.;Catania G.;Lucci D.;Bianchini F.;Puodziukynas A.;Kavoliuniene A.;Barauskiene V.;Aidietis A.;Barysiene J.;Vysniauskas V.;Zukauskiene I.;Kazakeviciene N.;Georgievska-Ismail L.;Poposka L.;Vataman E.;Grosu A. A.;op Reimer W. S.;de Swart E.;Lenzen M.;Jansen C.;Brons R.;Tebbe H.;van Hoogenhuyze D. C. A.;Veerhoek M. J.;Kamps M.;Haan D.;van Rijn N.;Bootsma A.;Baur L.;van den A.;Fransen H.;Eurlings L.;Meeder J.;De Boer M. J.;Winter J.;Broers H.;Werter C.;Bijl M.;Versluis S.;Milkowska M.;Wozakowska-Kaplon B.;Janion M.;Lepska L.;Swiatecka G.;Kokowicz P.;Cybulski J.;Gorecki A.;Szulc M.;Rekosz J.;Manczak R.;Wnuk-Wojnar A. -M.;Trusz-Gluza M.;Rybicka-Musialik A.;Myszor J.;Szpajer M.;Cymerman K.;Sadowski J.;Sniezek-Maciejewska M.;Ciesla-Dul M.;Gorkiewicz-Kot I.;Grodzicki T.;Rewiuk K.;Kubik L.;Lewit J.;de Sousa J. M. F. R.;Ferreira R.;Freitas A.;Morais J. C. A.;Pires R.;Gomes M. J. V.;Gago P.;Candeias R. A. C.;Nunes L.;Sa J. V. M.;Ventura M.;de Oliveira M.;Alves L. B.;Bostaca I.;Olariu C. T.;Dan G. A.;Dan A.;Podoleanu C.;Frigy A.;Georgescu G. I. M.;Arsenescu C.;Statescu C.;Sascau R.;Dimitrascu D. L.;Rancea R.;Shubik Y. V.;Duplyakov D.;Shalak M.;Danielyan M.;Galyavich A.;Zakirova V.;Hatala R.;Kaliska G.;Kmec J.;Zupan I.;Tasie` J.;Vokac D.;Edvardsson N.;Poci D.;Gamra H.;Denguir H.;Sepetoglu A.;Arat-Ozkan A.;Orynchak M.;Paliy E.;Vakalyuk I.;Malidze D.;Prog R.;Yabluchansky M. I.;Makienko N. V.;Potpara T.;Knezevic S.;Randjelovic M.
2018-01-01
Abstract
Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF, and MACCE. Echocardiographic LVH was present in 33% of 379 hypertensive patients. AF progression after 1 year occurred in 10.2% of 373 patients with rhythm follow-up. In hypertensive patients with LVH, AF progression occurred more frequently as compared with hypertensive patients without LVH (23.3% vs 8.8%, p = 0.011). In hypertensive AF patients, LVH was the most important multivariably adjusted determinant of AF progression on multivariable logistic regression (odds ratio 4.84, 95% confidence interval 1.70 to 13.78, p = 0.003). This effect was only seen in male patients (27.5% vs 5.8%, p = 0.002), while in female hypertensive patients, no differences were found in AF progression rates regarding the presence or absence of LVH (15.2% vs 15.0%, p = 0.999). No differences were seen in MACCE for hypertensive patients with and without LVH. In conclusion, in men with hypertension, LVH is associated with AF progression. This association seems to be absent in hypertensive women.
Erkuner O., Dudink E.A.M.P., Nieuwlaat R., Rienstra M., Van Gelder I.C., Camm A.J., et al. (2018). Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). THE AMERICAN JOURNAL OF CARDIOLOGY, 122(4), 578-583 [10.1016/j.amjcard.2018.04.053].
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/365108
Citazioni
5
15
11
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
